184358-81-4

Basic information

• Product Name: 4-(3'-chloro-4'-fluoroanilino)-6-hydroxyquinazoline
• Synonyms: 4-(3'-chloro-4'-fluoroanilino)-6-hydroxyquinazoline
• CAS NO: 184358-81-4
• Molecular Weight: 289.696
• Mol File: 184358-81-4.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 4-(3'-chloro-4'-fluoroanilino)-6-hydroxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3'-chloro-4'-fluoroanilino)-6-hydroxyquinazoline(184358-81-4)
• EPA Substance Registry System: 4-(3'-chloro-4'-fluoroanilino)-6-hydroxyquinazoline(184358-81-4)

Safety Data

• Hazardous Substances Data: 184358-81-4(Hazardous Substances Data)

Upstream product

• 184358-80-3 6-acetoxy-4-(3'-chloro-4'-fluoroanilino)quinazoline 
• 179688-15-4 4-hydroxyquinazoline-6-yl acetate 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 394-31-0 2-amino-5-hydroxybenzoic acid 
• 16064-10-1 6-hydroxyquinazolin-4(3H)-one 
• 179688-15-4 3,4-dihydro-4-oxoquinazolin-6-yl acetate 
• 179246-11-8 4-chloroquinazoline-6-yl acetate 
• 16064-10-1 6-hydroxyquinazolin-4(3H)-one 

Downstream Products

• 1012057-27-0 ethyl 2-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yloxy)acetate 
• 184358-79-0 4-(3'-chloro-4'-fluoranilino)-6-(3-morpholinopropoxy)quinazoline 
• 1259017-70-3 N-(3-chloro-4-fluorophenyl)-6-(3-chloropropoxy)quinazolin-4-amine 
• 1259017-42-9 3-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yloxy)propyl 4-methylpiperazine-1-carbodithioate 
• 1012054-60-2 2-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yloxy)-N-hydroxyacetamide 
• 1012057-29-2 Ethyl 7-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yloxy)heptanoate 
• 184358-80-3 6-acetoxy-4-(3'-chloro-4'-fluoroanilino)quinazoline 

Relevant articles and documents

Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines

On the basis of combination strategy, a novel series of EGFR inhibitors were designed and synthesized by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. The effect of the synthesized compounds on cell proliferation was evaluated by MTT assay in three human cancer cell lines: MDA-MB-468, SK-BR-3 and HCT-116. Two compounds (11d and 11f) were found more potent against all three cell lines and five compounds (11a, 11d-11g) were found more potent against both MDA-MB-468 and SK-BR-3 than Lapatinib. SAR studies revealed that the substituents on C6 and C7 positions of quinazoline, the amine component of dithiocarbamate moiety and the linker greatly affected the activity. This work provides a promising new strategy for the preparation of potent tyrosine kinase inhibitors.

FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS

The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.